A little-known small-cap company is preparing to revolutionize preventative healthcare-and with FDA clinical trials on the horizon, investors are watching closely.

Prevention is the future of healthcare, and one fast-growing health-tech firm is developing an AI platform that could transform early detection of diseases like diabetes and Alzheimer's. Unlike trend-driven sectors, healthcare remains a constant need-and health-tech is quickly becoming one of the highest-impact investment sectors of the 21st century.
Governments, insurers, and patients are demanding care that's better, more affordable, and more accessible-and they're turning to health-tech to deliver it.
Why pay attention now?
Because this company is positioned right at the intersection of artificial intelligence and healthcare-two of the fastest-growing and most transformative global sectors. With a proprietary AI platform and a bold mission to improve early disease detection, this small-cap firm is not just another tech player-it's a mission-driven innovator leading the charge in preventative medicine.
Through a joint venture, the company is developing Vision AI, an advanced diagnostic platform that can detect retinal diseases like diabetic retinopathy within seconds. Using a simple fundus eye test paired with powerful AI algorithms, Vision AI helps catch diabetes early-before serious complications like blindness occur.
This technology is scalable, fast, and potentially game-changing for millions affected by chronic diseases. Early detection remains one of healthcare's biggest unmet needs-and this platform is aiming to meet it head-on.
Companies that achieve FDA clearance (510(k)) or CE marking for early disease detection tools often gain massive credibility-and the attention of major players like Google (Verily), Apple (HealthKit), and Medtronic, all of whom are actively acquiring or partnering with innovators in this space.
This company is now gearing up for FDA clinical trials.
Learn how this milestone could unlock major value-and potentially generate exponential upside for early investors.

This message is a paid advertisement for Avant Technologies Inc., (OTCMKTS: AVAI) from Interactive Offers. It's Today Media, LLC. receives a fixed fee for each subscriber that clicks on a link in this email, totaling up to $5,500.00. Other than the compensation received for this advertisement sent to subscribers, It's Today Media and its principals are not affiliated with Interactive Offers. It's Today Media and its principals do not own any of the stocks mentioned in this email or in the article that this email links to. Neither It's Today Media nor its principals are FINRA-registered broker-dealers or investment advisers. The content of this email should not be taken as advice, an endorsement, or a recommendation from It's Today Media to buy or sell any security. It's Today Media has not evaluated the accuracy of any claims made in this advertisement. It's Today Media recommends that investors do their own independent research and consult with a qualified investment professional before buying or selling any security. Investing is inherently risky. Past-performance is not indicative of future results. Please see the disclaimer regarding Avant Technologies Inc., (OTCMKTS: AVAI) on Interactive Offer's website for additional information about the relationship between Interactive Offers and Avant Technologies Inc., (OTCMKTS: AVAI).